Pieris Pharmaceuticals (NASDAQ:PIRS) Upgraded at StockNews.com

StockNews.com upgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a sell rating to a hold rating in a report issued on Monday morning.

Pieris Pharmaceuticals Stock Performance

Shares of PIRS opened at $16.10 on Monday. Pieris Pharmaceuticals has a 52-week low of $6.20 and a 52-week high of $22.32. The business’s 50 day moving average price is $16.69 and its two-hundred day moving average price is $13.70. The firm has a market cap of $21.25 million, a PE ratio of -0.86 and a beta of 0.66.

Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($2.76) earnings per share (EPS) for the quarter. Pieris Pharmaceuticals had a negative net margin of 39.71% and a negative return on equity of 101.29%.

Hedge Funds Weigh In On Pieris Pharmaceuticals

A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. BML Capital Management LLC bought a new position in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 42,130 shares of the biotechnology company’s stock, valued at approximately $699,000. Pieris Pharmaceuticals accounts for about 0.4% of BML Capital Management LLC’s investment portfolio, making the stock its 21st biggest position. BML Capital Management LLC owned 3.19% of Pieris Pharmaceuticals at the end of the most recent reporting period. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.